Results 111 to 120 of about 1,425 (166)

[Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease: Association with Disease Activity and its Impact on Quality of Life]. [PDF]

Acta Gastroenterol Latinoam
Briz CM, Cassella FI, Perez PM, Marzullo S, Viola L.   +4 more
europepmc   +1 more source

Identifying key clinical and biochemical predictors of treatment outcomes in inflammatory bowel disease: a real-world evidence study. [PDF]

Sci Rep
Rodríguez JLG, Parrado CV, Cordero-Ramos J, Bouallou A, Armengol de la Hoz MÁ, Arias FA.   +5 more
europepmc   +1 more source

Is a rare <i>CXCL8</i> gene variant a new possible cause or course factor of inflammatory bowel disease? [PDF]

Front Immunol
Gabryel M, Zakerska-Banaszak O, Ladziak K, Hubert KA, Baturo A, Suszynska-Zajczyk J, Hryhorowicz M, Dobrowolska A, Skrzypczak-Zielinska M.   +8 more
europepmc   +1 more source

Secondary bile acid lithocholic acid ameliorates colitis-like inflammation in a human intestine-on-chip system. [PDF]

Front Immunol
Kaden T, Allwang M, Stallhofer J, Graf K, Raasch M, Mosig AS.   +5 more
europepmc   +1 more source

Olmesartan-Induced Gastropathy: An Important Cause to Think about in Refractory Peptic Ulcer Disease. [PDF]

GE Port J Gastroenterol
Simas D, Gonçalves AR, Gomes P, Russo P, Amado CM, Vasconcelos H.   +5 more
europepmc   +1 more source

Development and validation of the FR-QoL-29-Dutch (Flemish) Questionnaire and assessment of clinical factors associated with food-related quality of life in a Belgian inflammatory bowel disease population: a cross-sectional study. [PDF]

BMJ Open Gastroenterol
Wellens J, Guadagnoli L, Vanderstappen J, Hoekx S, Vandaele J, Verstockt B, Ferrante M, Whelan K, Vermeire S, Sabino J.   +9 more
europepmc   +1 more source

Shared decision-making improves adherence to mesalamine in ulcerative colitis: A prospective, multicenter, non-interventional cohort study in Germany. [PDF]

World J Gastroenterol
Kruis W, Jessen P, Morgenstern J, Reimers B, Müller-Grage N, Bokemeyer B.   +5 more
europepmc   +1 more source

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU. [PDF]

Gut
Gisbert JP, Donday MG, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Leo Carnerero E, Merino O, Nantes Castillejo Ó, Navarro P, Van Domselaar M, Gutiérrez A, Alonso-Abreu I, Mejuto R, Fernández-Salazar L, Iborra M, Martín-Arranz MD, Pineda JR, Sampedro MJ, Serra Nilsson K, Bouhmidi A, Batista L, Muñoz Villafranca C, Rodríguez-Lago I, Ceballos D, Guerra I, Mañosa M, Marín Jiménez I, Torrella E, Vera Mendoza M, Casanova MJ, de Francisco R, Arias-González L, Marín Pedrosa S, García-Bosch O, García-Alonso FJ, Delgado-Guillena P, García MJ, Torrealba L, Núñez-Ortiz A, Vicuña Arregui M, Bosca-Watts MM, Blázquez I, Acosta D, Garre A, Baldán M, Martínez C, Barreiro-de Acosta M, Domènech E, Esteve M, García-Sánchez V, Nos P, Panés J, Chaparro M, EXIT Study group of GETECCU.   +58 more
europepmc   +1 more source

[Synchronous medullary and mucinous tumor in the right colon: case report] [PDF]

Rev Fac Cien Med Univ Nac Cordoba
Bastidas J, Posada H, Amante M, Pestalardo L, Muthular M, Stawkowy L, Petracchi E, Yazyi F.   +7 more
europepmc   +1 more source

[Application of advanced treatment in chronic inflammatory bowel diseases]. [PDF]

Inn Med (Heidelb)
Misselwitz B, Zeißig S, Schreiber S, Dignass A.   +3 more
europepmc   +1 more source